Total Payments
$83,978
2024 Payments
$40,280
Companies
49
Transactions
487
Medicare Patients
2,555
Medicare Billing
$268,120
Payment Breakdown by Category
Research$68,006 (81.0%)
Food & Beverage$9,998 (11.9%)
Consulting$3,281 (3.9%)
Travel$1,366 (1.6%)
Other$1,200 (1.4%)
Education$127.06 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $68,006 | 6 | 81.0% |
| Food and Beverage | $9,998 | 469 | 11.9% |
| Consulting Fee | $3,281 | 3 | 3.9% |
| Travel and Lodging | $1,366 | 2 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,200 | 1 | 1.4% |
| Education | $127.06 | 6 | 0.2% |
Payments by Type
Research
$68,006
6 transactions
General
$15,972
481 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $68,006 | 6 | $0 (2024) |
| ABBVIE INC. | $5,364 | 65 | $0 (2024) |
| Janssen Research & Development, LLC | $1,662 | 8 | $0 (2018) |
| Amgen Inc. | $956.64 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $911.53 | 41 | $0 (2024) |
| Lilly USA, LLC | $890.55 | 46 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $717.76 | 32 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $533.04 | 18 | $0 (2024) |
| Esperion Therapeutics, Inc. | $477.15 | 19 | $0 (2024) |
| Amarin Pharma Inc. | $450.63 | 17 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,280 | 46 | Eli Lilly and Company ($39,379) |
| 2023 | $2,440 | 36 | AbbVie Inc. ($1,785) |
| 2022 | $2,513 | 60 | ABBVIE INC. ($1,627) |
| 2021 | $1,822 | 108 | MannKind Corporation ($330.63) |
| 2020 | $1,180 | 62 | Esperion Therapeutics, Inc. ($167.43) |
| 2019 | $2,700 | 48 | Eli Lilly and Company ($1,690) |
| 2018 | $30,708 | 90 | Eli Lilly and Company ($26,938) |
| 2017 | $2,336 | 37 | AbbVie, Inc. ($1,353) |
All Payment Transactions
487 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $146.58 | General |
| Category: Automated insulin delivery system | ||||||
| 12/12/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $15.28 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Automated insulin delivery system | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: Cardiology | ||||||
| 11/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Gastroenterology | ||||||
| 11/04/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/22/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.31 | General |
| 10/10/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Endocrinology | ||||||
| 10/07/2024 | Eli Lilly and Company | — | — | In-kind items and services | $947.54 | Research |
| Study: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES | ||||||
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: DIABETES | ||||||
| 09/17/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart, Flector | Food and Beverage | Cash or cash equivalent | $13.97 | General |
| Category: Endocrinology | ||||||
| 09/16/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 09/12/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $46.34 | General |
| Category: Immunology | ||||||
| 09/09/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $31,056.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/05/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/04/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Automated insulin delivery system | ||||||
| 08/19/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Endocrinology | ||||||
| 08/08/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: Diabetes | ||||||
| 08/06/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Cardiology | ||||||
| 07/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: DIABETES | ||||||
| 07/18/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Diabetes Care | ||||||
| 07/18/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Diabetes Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $31,056 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $28,628 | 3 |
| A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES | Eli Lilly and Company | $947.54 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 744 | 2,598 | $262,704 | $98,096 |
| 2022 | 17 | 737 | 1,858 | $207,526 | $84,869 |
| 2021 | 13 | 508 | 751 | $75,464 | $47,126 |
| 2020 | 14 | 566 | 831 | $63,581 | $38,029 |
Total Patients
2,555
Total Services
6,038
Medicare Billing
$268,120
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 43 | 655 | $52,400 | $18,403 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 201 | $30,150 | $16,621 | 55.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 46 | 431 | $43,100 | $14,469 | 33.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 112 | 112 | $16,800 | $13,354 | 79.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 46 | 366 | $73,200 | $11,753 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 86 | 127 | $15,240 | $7,287 | 47.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 75 | $7,125 | $4,613 | 64.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 30 | 30 | $2,400 | $2,274 | 94.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 15 | $3,570 | $1,952 | 54.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 22 | 29 | $3,190 | $1,762 | 55.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 18 | $2,898 | $1,754 | 60.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 44 | 169 | $4,394 | $1,605 | 36.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 34 | 34 | $1,350 | $969.00 | 71.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 24 | $1,440 | $883.56 | 61.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 27 | 37 | $1,850 | $343.54 | 18.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 33 | 102 | $2,040 | $38.65 | 1.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 32 | 173 | $1,557 | $15.22 | 1.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 215 | $32,250 | $16,924 | 52.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 107 | 107 | $16,050 | $13,229 | 82.4% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 55 | 326 | $65,200 | $12,486 | 19.2% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 49 | 265 | $26,500 | $9,677 | 36.5% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 41 | 275 | $22,000 | $8,330 | 37.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 87 | 117 | $14,040 | $7,086 | 50.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 104 | $9,880 | $5,860 | 59.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 32 | 32 | $2,560 | $2,248 | 87.8% |
About Dr. David Deatkine, MD
Dr. David Deatkine, MD is a Internal Medicine healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336255850.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Deatkine, MD has received a total of $83,978 in payments from pharmaceutical and medical device companies, with $40,280 received in 2024. These payments were reported across 487 transactions from 49 companies. The most common payment nature is "" ($68,006).
As a Medicare-enrolled provider, Deatkine has provided services to 2,555 Medicare beneficiaries, totaling 6,038 services with total Medicare billing of $268,120. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Birmingham, AL
- Active Since 08/21/2006
- Last Updated 01/16/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336255850
Products in Payments
- ARMOUR THYROID (Drug) $1,781
- Androgel (Drug) $1,349
- JARDIANCE (Drug) $789.64
- Repatha (Biological) $588.31
- FARXIGA (Drug) $507.26
- Vascepa (Drug) $450.63
- AFREZZA (Drug) $392.78
- NEXLETOL (Drug) $371.35
- UBRELVY (Drug) $334.35
- Korlym (Drug) $313.66
- BAQSIMI (Drug) $275.72
- TRADJENTA (Drug) $263.10
- TOUJEO (Drug) $237.39
- MOUNJARO (Drug) $234.78
- STEGLATRO (Drug) $223.19
- Prolia (Biological) $209.48
- SOLIQUA (Drug) $189.13
- iLet Bionic Pancreas (Device) $188.65
- NATPARA (Drug) $169.79
- LEQVIO (Drug) $154.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Birmingham
Ryan Weldon, M.d, M.D
Internal Medicine — Payments: $380,099
Internal Medicine $380,099
Rudolph Navari, M.d, M.D
Internal Medicine — Payments: $335,135
Internal Medicine $335,135
Dr. Robert Lewis, M.d, M.D
Internal Medicine — Payments: $176,028
Internal Medicine $176,028
Dr. James Sullivan, Md, MD
Internal Medicine — Payments: $146,354
Internal Medicine $146,354
Jose Vargas, M.d, M.D
Internal Medicine — Payments: $140,921
Internal Medicine $140,921
Dr. Jordan Vaughn, M.d, M.D
Internal Medicine — Payments: $90,874
Internal Medicine $90,874